LYEL

Conviction 24HealthcareScan · Thu, Jun 25, 2026

LYEL$12.49-3.92%

ResistanceSupportVol 14

Vol MA14 158.47K

Mar 26Apr 14May 1May 19Jun 8Jun 25

Lyell Immunopharma, Inc.PHARMACEUTICAL PREPARATIONSwww.lyell.com ↗

Price12.49

Change-3.92%

Gap+1.62%

Rel volume1.57×

Avg volume154.12K

Avg $ vol2.02M

SMA 2013.53

SMA 5017.62

SMA 20020.78

Price vs 50-29.11%

Price vs 200-39.88%

MA stackbearish

50/200 cross—

Supertrenddown · 15.87

RSI (14)37

MACD hist0.19

MACD crossbull · 7d

Stoch %K / %D33 / 39

ADX (14)38

+DI / −DI15 / 23

RSI divergence—

MACD divergence—

ATR %+9.80%

ADR %9.06%

52w high38.60

52w low8.84

From 52w high-67.64%

Above 52w low+41.29%

New 52w highNo

SqueezeOff

Bollinger width48.41%

%B0.34

Donchian pos13.86%

Donchian high17.65

Donchian low11.66

AVWAP (52w high)21.98

vs AVWAP high-43.17%

AVWAP (52w low)19.62

vs AVWAP low-36.34%

OBV trendFlat

Chaikin MF (20)-0.14

Today vs 20d1.57×

Avg vol (14d)158.47K

Avg vol (20d)154.12K

Avg $ vol (20d)2.02M

Market cap291.44M

RS 3m (vs SPY)-46.27%

RS 6m (vs SPY)-68.73%

RS line new highNo

Trend template3/8

Technical rank9.6

1 week-0.24%

1 month-23.70%

3 months-37.98%

6 months-66.58%

1 year+30.31%

YTD-56.90%

P/E-1.06

P/B1.06

P/S—

P/FCF-1.93

EPS-16.06

Div yield—

ROE-100.29%

ROA-78.27%

Debt/Eq—

Current7.23

EV/EBITDA-0.78

Gross margin—

Net margin—

Rev growth-40.98%

EPS growth19.98%

Price target—

Target upside—

Analyst rating—

Institutional—

Ent. value200.67M

Revenue2K

Net income-24.15M

Gross profit—

Free cash flow-150.8M

IndustryPHARMACEUTICAL PREPARATIONS

ExchangeNasdaq

Shares out23.33M

Employees161

ListedThu, Jun 17, 2021

Free float6.6M

Float %31.1%

Short interest1.35M

Days to cover16.2d

Short volume42.3%

Squeeze score75 / 100

Next earnings—

EPS forecast—

Last EPS vs est—

Last surprise—

Setup gradeD

Conviction24 / 100

Pattern quality—

Tech rank9.6 / 100

Group rank50 / 100

Status laneNo active setup

Setup direction—

Pattern family

Resistance18.59

Support11.68

Days since event—

Candle confirm—

News sentiment—

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in LYEL

All disclosures →

No recent disclosed trades by Congress in LYEL. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in LYEL · 2 buys · 1 sell

Insider	Side	Shares	Value	Traded	Filed
Innovative Cellular Therapeutics Holdings Ltd 10% owner · Common Stock · 2026-06-15	Dispose	66.5K	—	2026-06-15	2026-06-18
BRAWLEY OTIS W Director · Option (right to buy) · 2026-06-10	Grant	9.25K	—	2026-06-10	2026-06-12
Bachleda Mark Director · Option (right to buy) · 2026-06-10	Grant	9.25K	—	2026-06-10	2026-06-12

SEC filings

EDGAR filings in LYEL · 2 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.

Start free — 7-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.